Moxifloxacin is a member of the fluoroquinolone class of antibacterial agents. It has broad spectrum of activity and antibacterial action. It exerts activity against a wide range of Gram-positive, Gram-negative, anaerobic and atypical bacteria including Mycoplasma pneumoniae. The bactericidal action results from the inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV which are required for bacterial DNA replication, transcription & repair.
Optimox® Tablet: Each film coated tablet contains Moxifloxacin Hydrochloride BP equivalent to Moxifloxacin 400 mg.
Optimox® IV Infusion: Each 250 ml sterile solution contains Moxifloxacin Hydrochloride BP equivalent to Moxifloxacin 400 mg.
Optimox® is indicated for treating the following infections caused by
● Community acquired pneumonia
● Exacerbation of chronic bronchitis
● Skin and soft tissue infections
● Pelvic inflammatory disease
● Complicated intra-abdominal infections etc.
Tablet & IV Infusion:
The dose of Optimox® is 400 mg (orally or as an intravenous infusion)
once every 24 hours. The duration of therapy depends on the type of
infections as described in the following table:
Optimox® IV Infusion can be administered intravenously for the entire
treatment duration. Alternatively, therapy may be initial intravenous
administration, followed by oral administration when clinically indicated.
No dosage adjustment is required in patients with renal or hepatic
One Optimox® Tablet once a day.
1. Before use please check the bottle against a light source prior
2. Do not use if the solution is turbid or contains particles.
3. Optimox® IV should be administered by intravenous infusion
over period of 60 minutes.
4. Avoid bolus or rapid infusion.
5. Discard any unused portion.
6. Do not refrigerate.
Optimox is contraindicated in the patients with known hypersensitivity to Moxifloxacin or other quinolones.
Moxifloxacin has been shown to prolong the QT interval in some patients. It should be avoided in patients with known prolongation, hypokalemia and with drugs that prolong the QT interval. It may cause increased risk of tendinitis and tendon rupture. It should be discontinued if pain or inflammation in a tendon occurs.
Most side effects reported with moxifloxacin treatment are mild tomoderate in nature and require no treatment. Most common adverse reactions are nausea, diarrhea, headache, dizziness, retinal detachment, tendinitis & tendon rupture.
Antacids, sucralfate, multivitamins and other products containing multivalent cations reduces the absorption of Moxifloxacin. Moxifloxacin should be administered 4 hours before or 8 hours after antacids, sucralfate, multivitamins and other products with multivalent cations. It may enhance anticoagulant effect of warfarin and proarrythmic effect of Class IA and Class III antiarrhythmics. So concomitant use of Moxifloxacin with them should be avoided. No clinically significant drug interactions of theophylline, digoxin, or glyburide have been observed with Moxifloxacin
Use in Pregnancy:
Moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus as there are no adequate and well-documented studies in pregnant women.
Use in Lactating Mother:
Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when Moxifloxacin eye drops & eye ointment is administered to a lactating mother.
Pediatric Use: The safety and effectiveness of Moxifloxacin eye drops & eye ointment in infants below one year of age was not proven earlier. However, several latest clinical studies show that the drug can be used safely in children even younger than one month of age.
Optimox® Tablet: Each box contains 10 tablets in blister pack.
Optimox® IV Infusion: Each box contains 250 ml bottle of sterile solution for IV Infusion.
Aristopharma Ltd. is one of the top 10 pharmaceutical companies in Bangladesh. The company started its journey in 1986 with the honest promise to provide quality medicines at affordable prices to the countrymen.
© 2024. Aristopharma Ltd. All rights reserved.